Live tape
Top 8, mentions 7d7,505META2,263 mentions▲ +0.06GOOGL1,504 mentions▲ +0.02NVDA797 mentions▲ +0.09MUSE665 mentions▲ +0.07MSFT602 mentions▲ +0.05SPY567 mentions▲ +0.05QQQ557 mentions▲ +0.08TSLA550 mentions▲ +0.06

Equity · Healthcare

BIIB

Biogen Inc. · NasdaqGS

$227.62 +0.53% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 25, 2026
Price · Chart
Our own end-of-day closes 62 sessions
$230 $190 30 Jun 25 Sep

The line runs $216 on 30 June through $227.62 on 25 September, on a scale from $190 to $230. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of BIIB over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 62 sessions over that window: $216 on 30 June 2026 through $227.62 on 25 September 2026.

Market cap $33.6B
P/E (TTM) 24.5
52-week range $136 – $227.62
Avg volume 44.4K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Sep 25, 2026

BIIB insider trades

SEC Form 4 · last 90 days · newest reported trade 4 Aug 2026
Open-market buys 0
Open-market sells 2
Net sold $240K
Non-trade filings 0
Date Insider Type Shares Value
04 Aug 2026 Minor Lloyd Director Sell 593 $119K
03 Aug 2026 Minor Lloyd Director Sell 593 $121K

BIIB reported financials

SEC EDGAR XBRL

BIIB reported revenue of $9.9B for the fiscal year ended 31 Dec 2025. Net income over the same period was $1.3B.

Figure Reported Period
Revenue $9.9B 31 Dec 2025 fiscal year
Net income $1.3B 31 Dec 2025 fiscal year
Diluted EPS $8.79 31 Dec 2025 fiscal year
Total assets $29.5B 31 Mar 2026 at period end
Total equity incl. minority interest $18.7B 31 Mar 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 31 Mar 2026

BIIB earnings

SEC EDGAR
Date Period EPS Revenue
31 Mar 2026 Q1 2026 $2.15 $2.48B
31 Dec 2025 FY 2025 $8.79 $9.89B
30 Sep 2025 Q3 2025 $3.17 $2.53B
30 Jun 2025 Q2 2025 $4.33 $2.65B
31 Mar 2025 Q1 2025 $1.64 $2.43B
31 Dec 2024 FY 2024 $11.18 $9.68B
30 Sep 2024 Q3 2024 $2.66 $2.47B
30 Jun 2024 Q2 2024 $4.00 $2.46B

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

BIIB institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a BIIB position for the quarter ended 30 Jun 2026 — a combined $736.2M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
AQR Capital Management Held (±25%) +0.7% shares 1,936,859 $416.9M
Citadel Advisors Added +203.0% shares 418,356 $90.4M
Fisher Asset Management Held (±25%) +8.1% shares 338,018 $73.0M
Balyasny Asset Management Trimmed −59.2% shares 265,090 $57.3M
Man Group Trimmed −38.4% shares 196,222 $42.4M
Point72 Asset Management Trimmed −89.1% shares 88,149 $19.0M
Renaissance Technologies Trimmed −61.8% shares 77,744 $16.8M
D. E. Shaw & Co. New position 74,438 $16.1M
Marshall Wace Trimmed −94.5% shares 12,595 $2.7M
Two Sigma Investments Held (±25%) −24.8% shares 7,105 $1.5M

Source: SEC EDGAR 13F filings

BIIB fails-to-deliver

SEC CNS data

On 28 Aug 2026, 991 shares of BIIB failed to deliver (about $220K).

Settlement date Shares failed Notional % of shares out
28 Aug 2026 991 $220K 0.001%
25 Aug 2026 3,091 $674K 0.002%
24 Aug 2026 93 $20K <0.001%
21 Aug 2026 145 $31K <0.001%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in BIIB

STOCK Act disclosures

The most recent congressional trade disclosed in BIIB is a sale by Kevin Hern (house, OK), dated 18 Aug 2026.

Date Member Type Amount
18 Aug 2026 filed 01 Sep 2026 Kevin Hern house · Republican–OK Sale $1K–$15K
12 May 2026 filed 08 Jun 2026 Maria Elvira Salazar house · Republican–FL Purchase $1K–$15K
30 Jan 2026 filed 13 Feb 2026 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K

Source: U.S. House of Representatives financial disclosures